Understanding Higher Risk MDS and the Transition to AML @AAMDSIF
Understanding Higher Risk MDS and the Transition to AML @AAMDSIF
Uploaded January 2025 | Updated September 2026, 1 day ago
Presented by Dale Schaar, MD, PhD, dhis session will provide a comprehensive overview of high risk MDS and the transition to AML, from diagnosis to treatment.
For more like this, please watch "What Are My Options with High Risk MDS/AML" here: aamds.org/webinar/what-are-my-options-high-risk-mdsaml-spring-2021-conference
Understanding Higher Risk MDS and the Transition to AMLTransplantation for Bone Marrow Failure with Amy DeZern, MD, MS and Richard Childs, MDDr. Rory Shallis explains new FDA approval for imetelstatExpanded Access to Reblozyl® for Patients with Dr. Guillermo Garcia ManeroPNH and Non Transplant Therapies, from the 2023 New Haven Patient and Family ConferenceWhat is PNH? Webinar recording with Dr. Caroline Piatek2022 Miami Patient and Family Hybrid Conference: PNH with Dr. Damian LaberTransplants for MDS and Severe Aplastic Anemia - 2023 Omaha Patient and Family Hybrid ConferenceThe Future of Clinical Trials for Bone Marrow FailureRecent FDA Approval of Danicopan for patients with PNHTransplant for Severe Aplastic Anemia (Pediatric) - 2022 Memphis Patient & Family ConferencePanel Discussion: Addressing the Gaps in Serving Transplant Patients
AAMDSIF |

Understanding Higher Risk MDS and the Transition to AML

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER